{
    "info": {
        "nct_id": "NCT04835805",
        "official_title": "A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy",
        "inclusion_criteria": "* ECOG Performance Status of 0 or 1\n* Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, that has progressed on or after treatment with anti-PD-1 or anti-PD-L1 therapy. Patients may have received up to two lines of systemic cancer therapy. Treatment with anti-PD-1/PD-L1 in the adjuvant setting is acceptable. Patients must have progressed disease at study entry\n* Documentation of NRAS mutation-positive within 5 years prior to screening\n* Tumor specimen availability\n* Adequate hematologic and end-organ function\n* Measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with a pan-RAF inhibitor\n* Treatment with systemic immunotherapy agents (e.g., anti-CTLA4, anti-PD(L)1, cytokine therapy, investigational therapy, etc.) within 28 days prior to C1D1\n* Symptomatic, untreated, or actively progressing CNS metastases\n* History or signs/symptoms of clinically significant cardiovascular disease\n* Known clinically significant liver disease\n* History of autoimmune disease or immune deficiency\n* Prior treatment with a MEK inhibitor (cobimetinib arm)\n* History of or evidence of retinal pathology on ophthalmologic examination (cobimetinib arm)\n* History of immune-related AE attributed to prior anti-PD(L)1 therapy that resulted in permanent discontinuation of anti-PD(L)1 therapy (nivolumab arm)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, that has progressed on or after treatment with anti-PD-1 or anti-PD-L1 therapy. Patients may have received up to two lines of systemic cancer therapy. Treatment with anti-PD-1/PD-L1 in the adjuvant setting is acceptable. Patients must have progressed disease at study entry",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed ... cutaneous melanoma",
                    "criterion": "cutaneous melanoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III)",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "Stage III unresectable locally advanced",
                                "Stage IV metastatic (recurrent or de novo)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that has progressed on or after treatment with anti-PD-1 or anti-PD-L1 therapy",
                    "criterion": "progression on anti-PD-1 or anti-PD-L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "anti-PD-1",
                                "anti-PD-L1"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients may have received up to two lines of systemic cancer therapy",
                    "criterion": "number of prior systemic cancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "maximum number of prior therapies",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with anti-PD-1/PD-L1 in the adjuvant setting is acceptable",
                    "criterion": "prior anti-PD-1/PD-L1 adjuvant therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior adjuvant therapy allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must have progressed disease at study entry",
                    "criterion": "disease status at study entry",
                    "requirements": [
                        {
                            "requirement_type": "progressed disease",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG Performance Status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status of 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documentation of NRAS mutation-positive within 5 years prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Documentation of NRAS mutation-positive",
                    "criterion": "NRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 5 years prior to screening",
                    "criterion": "NRAS mutation documentation date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": ">=",
                                "value": -5,
                                "unit": "years from screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor specimen availability",
            "criterions": [
                {
                    "exact_snippets": "Tumor specimen availability",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic and end-organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... end-organ function",
                    "criterion": "end-organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST v1.1",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known clinically significant liver disease",
            "criterions": [
                {
                    "exact_snippets": "Known clinically significant liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with a MEK inhibitor (cobimetinib arm)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a MEK inhibitor (cobimetinib arm)",
                    "criterion": "prior treatment with a MEK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunotherapy agents (e.g., anti-CTLA4, anti-PD(L)1, cytokine therapy, investigational therapy, etc.) within 28 days prior to C1D1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunotherapy agents (e.g., anti-CTLA4, anti-PD(L)1, cytokine therapy, investigational therapy, etc.) within 28 days prior to C1D1",
                    "criterion": "treatment with systemic immunotherapy agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to C1D1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of immune-related AE attributed to prior anti-PD(L)1 therapy that resulted in permanent discontinuation of anti-PD(L)1 therapy (nivolumab arm)",
            "criterions": [
                {
                    "exact_snippets": "History of immune-related AE attributed to prior anti-PD(L)1 therapy that resulted in permanent discontinuation of anti-PD(L)1 therapy (nivolumab arm)",
                    "criterion": "immune-related adverse event (AE) attributed to prior anti-PD(L)1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "attribution",
                            "expected_value": "prior anti-PD(L)1 therapy"
                        },
                        {
                            "requirement_type": "outcome",
                            "expected_value": "resulted in permanent discontinuation of anti-PD(L)1 therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of or evidence of retinal pathology on ophthalmologic examination (cobimetinib arm)",
            "criterions": [
                {
                    "exact_snippets": "History of or evidence of retinal pathology",
                    "criterion": "retinal pathology",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on ophthalmologic examination",
                    "criterion": "retinal pathology on ophthalmologic examination",
                    "requirements": [
                        {
                            "requirement_type": "evidence on examination",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of autoimmune disease or immune deficiency",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immune deficiency",
                    "criterion": "immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic, untreated, or actively progressing CNS metastases",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic ... CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated ... CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "actively progressing CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "actively progressing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or signs/symptoms of clinically significant cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "History ... of clinically significant cardiovascular disease",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "signs/symptoms of clinically significant cardiovascular disease",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "signs/symptoms",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with a pan-RAF inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a pan-RAF inhibitor",
                    "criterion": "prior treatment with pan-RAF inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}